Assays for measuring rivaroxaban: Their suitability and limitations

Therapeutic Drug Monitoring

Volumn 32, Issue 6, 2010, Pages 673-679

  Lindhoff Last, Edelgard ^a   Samama, Meyer Michel ^b,c   Ortel, Thomas L ^d   Weitz, Jeffrey I ^e   Spiro, Theodore E ^f  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b HÔTEL DIEU   (France)

^c Biomnis Laboratory   (France)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e MCMASTER UNIVERSITY   (Canada)

^f Bayer HealthCare Pharmaceuticals Inc   (United States)

Author keywords

anticoagulants; coagulation assays; monitoring; rivaroxaban

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A; DABIGATRAN ETEXILATE; RIVAROXABAN;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING TEST; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; DRUG OVERDOSE; HUMAN; INTERNATIONAL NORMALIZED RATIO; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTHROMBIN TIME; QUANTITATIVE ANALYSIS; REVIEW; THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CALIBRATION; DRUG MONITORING; FACTOR XA; HUMANS; MORPHOLINES; THIOPHENES;

EID: 78650271337     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181f2f264     Document Type: Review

References (52)

1. Roehrig S, Straub A, Pohlmann J, et al. Discovery of the novel antithrombotic agent 5-chloro-N-([(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl) phenyl]-1,3-oxazolidin-5-yl]methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct Factor Xa inhibitor. J Med Chem. 2005;48:5900-5908.
2. Depasse F, Busson J, Mnich J, et al. Effect of BAY 59-7939 a novel, oral, direct Factor Xa inhibitor on clot-bound Factor Xa activity in vitro. J Thromb Haemost. 2005;3(Suppl 1). Abstract P1104.
3. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 an oral, direct Factor Xa inhibitor. J Thromb Haemost. 2005;3:514-521.
4. Bayer Schering Pharma. Xarelto® Summary of Product Characteristics. 2009. Available at: www.xarelto.com/html/downloads/Xarelto-Summary-of- Product-Characteristics-May2009.pdf Accessed February 15, 2010.
5. Mueck W, Becka M, Kubitza D, et al. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban an oral, direct Factor Xa inhibitor in healthy subjects. Int J Clin Pharmacol Ther. 2007;45:335-344.
6. Mueck W, Eriksson BI, Bauer KA, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban an oral, direct factor Xa inhibitor in patients undergoing major orthopaedic surgery. Clin Pharmacokinet. 2008;47:203-216.
7. Walenga JM, Hoppensteadt DA. Monitoring the new antithrombotic drugs. Semin Thromb Hemost. 2004;30:683-695.
8. Weitz JI. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost. 2006;96:274-284.
9. Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64:292-303.
10. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet. 2009;48:1-22.
11. Carreiro J, Ansell J. Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict. Expert Opin Investig Drugs. 2008;17:1937-1945.
12. Frost C, Yu Z, Nepal S, et al. Apixaban, an oral direct Factor Xa inhibitor: single-dose safety, pharmacokinetics and pharmacodynamics in healthy volunteers. J Thromb Haemost. 2007;5(Suppl 1). Abstract P-M-665.
13. Samama MM, Le Flem L, Guinet C, et al. Effects of the novel, oral, direct Factor Xa inhibitor rivaroxaban on coagulation assays. Blood. 2008;112: Abstract 3028.
14. Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol. 2003;23:17-25.
15. Weitz JI, Bates SM. New anticoagulants. J Thromb Haemost. 2005;3: 1843-1853.
16. Kamal AH, Tefferi A, Pruthi RK. How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin Proc. 2007;82:864-873.
17. Zucker S, Cathey MH, Sox PJ, et al. Standardization of laboratory tests for controlling anticoagulant therapy. Am J Clin Pathol. 1970;53:348-354.
18. Poller L. International normalized ratios (INR): the first 20 years. J Thromb Haemost. 2004;2:849-860.
19. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008;133: 160S-198S.
20. Mueck W, Borris LC, Dahl OE, et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost. 2008;100:453-461.
21. Thachil J. ReleVance of clotting tests in liver disease. Postgrad Med J. 2008;84:177-181.
22. Buccheri G, Ferrigno D, Ginardi C, et al. Haemostatic abnormalities in lung cancer: prognostic implications. Eur J Cancer. 1997;33:50-55.
23. Munter G, Hershko C. Increased warfarin sensitivity as an early manifestation of occult prostate cancer with chronic disseminated intravascular coagulation. Acta Haematol. 2001;105:97-99.
24. Nahm CH, Choi JW, Lee J. Delta neutrophil index in automated immature granulocyte counts for assessing disease severity of patients with sepsis. Ann Clin Lab Sci. 2008;38:241-246.
25. Blonski W, Siropaides T, Reddy KR. Coagulopathy in liver disease. Curr Treat Options Gastroenterol. 2007;10:464-473.
26. Lindhoff-Last E, Piechottka GP, Rabe F, et al. Hirudin determination in plasma can be strongly influenced by the prothrombin level. Thromb Res. 2000;100:55-60.
27. Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78:412-421.
28. Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 an oral, direct Factor Xa inhibitor after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61:873-880.
29. Samama M, Martinoli JL, Perzborn E, et al. Evaluation of rivaroxaban calibrators and controls and the prothrombin time for measuring rivaroxaban plasma concentrations. Haemostaseologie. 2010;30:A114: Abstract P17-21.
30. Samama MM, Flem LL, Guinet C, et al. Effects of rivaroxaban, a novel, oral direct Factor Xa inhibitor, on coagulation assays. Br J Haematol. 2009;145(Suppl 1):35-36.
31. Smith SA, Morrissey JH. Thromboplastin composition affects the sensitivity of prothrombin time (PT) clotting tests to direct Factor Xa inhibitors. Blood. 2007;110:Abstract 928.
32. Walenga JM, Jeske WP, Hoppensteadt D, et al. Factor Xa inhibitors: today and beyond. Curr Opin Investig Drugs. 2003;4:272-281.
33. Tobu M, Iqbal O, Hoppensteadt D, et al. Anti-Xa and anti-IIa drugs alter international normalized ratio measurements: potential problems in the monitoring of oral anticoagulants. Clin Appl Thromb Hemost. 2004;10: 301-309.
34. Marlar RA, Kleiss AJ, Griffin JH. An alternative extrinsic pathway of human blood coagulation. Blood. 1982;60:1353-1358.
35. Samama MM, Martinoli JL, Leflem L, et al. Assessment of laboratory assays to measure rivaroxaban an oral, direct factor Xa inhibitor. Thromb Haemost. 2010;103:815-825.
36. Bates SM, Weitz JI. Coagulation assays. Circulation. 2005;112:e53-e60.
37. Smogorzewska A, Brandt JT, Chandler WL, et al. Effect of fondaparinux on coagulation assays: results of College of American Pathologists proficiency testing. Arch Pathol Lab Med. 2006;130:1605-1611.
38. Samama MM, Le Flem L, Guinet C, et al. Effects of rivaroxaban, a novel, oral, direct Factor Xa inhibitor, on coagulation assays. J Thromb Haemost. 2009;7:693.
39. Samama MM, Le Flem L, Guinet C, et al. Effect of the novel, oral, direct Factor Xa inhibitor rivaroxaban on coagulation assays. Haematologica. 2009;94:Abstract 0439.
40. Harder S, Parisius J, Picard-Willems B. Monitoring direct FXa-inhibitors and fondaparinux by prothrombinase-induced clotting time (PiCT): relation to FXa-activity and influence of assay modifications. Thromb Res. 2008;123:396-403.
41. Graff J, Picard-Willems B, Harder S. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a. Int J Clin Pharmacol Ther. 2007;45: 237-243.
42. Graff J, von Hentig N, Misselwitz F, et al. Effects of the oral, direct Factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol. 2007;47:1398-1407.
43. Berntorp E, Salvagno GL. Standardization and clinical utility of thrombin-generation assays. Semin Thromb Hemost. 2008;34:670-682.
44. Van Veen JJ, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol. 2008;142:889-903.
45. Gerotziafas GT, Elalamy I, Depasse F, et al. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct Factor Xa inhibitor rivaroxaban. J Thromb Haemost. 2007;5:886-888.
46. Klaeffling C, Piechottka G, Daemgen-von Brevern G, et al. Development and clinical evaluation of two chromogenic substrate methods for monitoring fondaparinux sodium. Ther Drug Monit. 2006;28:375-381.
47. Perzborn E, Harwardt M, Samama M. Assessment of Factor Xa chromogenic assays for measuring the pharmacodynamics of rivaroxaban an oral, direct Factor Xa inhibitor. J Thromb Haemost. 2009;7(Suppl 2):379. Abstract PP-MO-185.
48. Karst A, Bakowski-Enzian B, Perzborn E. Monitoring of rivaroxaban: suitability of a well-established chromogenic anti-Factor Xa assay. J Thromb Haemost. 2009;7(Suppl 2):372. Abstract PP-MO-162.
49. Samama MM, Le Flem L, Guinet C, et al. Suitability of chromogenic anti-FXa methods to measure rivaroxaban in human plasma. J Thromb Haemost. 2009;7(Suppl 2):693. Abstract PP-WE-199.
50. Samama M, Amiral J, Guinet C, et al. Specific and rapid measurement of rivaroxaban in plasma using a new, dedicated chromogenic assay. Haemostaseologie. 2010;30:A37:Abstract P01-17.
51. Perzborn E, Roehrig S, Straub A, et al. Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol. 2010;30:376-381.
52. Rohde G. Determination of rivaroxaban a novel, oral, direct Factor Xa inhibitor in human plasma by high-performance liquid chromatogra-phy-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;872:43-50.